Michael Schmidt, Ph.D.Chief Scientific Officer at Ankyra Therapeutics
Mike Schmidt, PhD, has served as Chief Scientific Officer at Ankyra since February 2020, where he oversees discovery, optimization, and preclinical characterization of Ankyra’s novel immune agonist therapeutics. Prior to joining Ankyra, Mike was VP of Antibody Discovery and later SVP, Head of Research at Compass Therapeutics where he led development of the company’s proprietary protein engineering platforms and discovery and optimization of multiple monoclonal and bispecific antibody leads including the CD137 agonist CTX-471 currently in Phase I studies. Before Compass, Mike was Associate Director of Protein Engineering at Eleven Biotherapeutics where he oversaw early stage discovery and optimization of antibody and non-antibody drugs for ocular diseases. In this role, he led development of EBI-031, an intravitreal IL-6 antagonist for treatment of diabetic macular edema licensed to Roche, as well as a modified albumin PK extension technology licensed to Albumedix. Mike received his PhD in biological engineering from MIT where his research focused on developing novel computational and experimental tools for improving antibody penetration in solid tumors. He earned his BS in biology from Villanova University.